pDONR223-MKNK2 Citations (1)
Originally described in: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA Nature. 2010 Dec 16;468(7326):968-72. doi: 10.1038/nature09627 PubMed Journal
Articles Citing pDONR223-MKNK2
| Articles |
|---|
| Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells. Brunet L, Alexandre D, Lee J, Blanquer-Rossello MDM, Bracquemond D, Guernet A, Chhouri H, Goupil M, Kherrouche Z, Arabo A, Mancini M, Cartier D, Yao S, Godefroy D, Dehedin J, Li JR, Duparc C, Jamme P, Vinchent A, Berard C, Tulasne D, Arena S, Bardelli A, Cheng C, Cho BC, Wurtz O, Coulouarn C, Maraver A, Aaronson SA, Cortot AB, Anouar Y, Grumolato L. Nat Commun. 2025 Aug 22;16(1):7853. doi: 10.1038/s41467-025-61788-w. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.